Abstract:Nanocarrier-based drug delivery systems are at the forefront of innovative research in the field of medical science, providing potential pathways for treatments across several routes of administration. Notably, a great deal of research has gone into maximizing the potential of polymeric nanoparticles and liposomes, with a focus on addressing the intricacies of lung cancer through the pulmonary route. The present research aims to improve the pharmacokinetic profiles of afatinib using a liposomal and polymeric nanoparticle dry powder approach rather than the afatinib plain drug solution to increase the survival rate and treatment of patients suffering from lung cancer. Formulated afatinib encapsulated PEGylated liposomal and afatinib loaded PLGA nanoparticles dry powder inhaler were characterized for the in-vivo pulmonary pharmacokinetics study using rat model upon intratracheal administration. The results of in-vivo pulmonary pharmacokinetics studies of both formulations indicated that it improved the pharmacokinetics profiles of the encapsulated agent (afatinib) by increasing the C max, AUC Total, Mean residence time (MRT) and decreasing the clearance (CL), and volume of distribution (V Z ) than the afatinib plain drug solution. Results suggested that the selective targeting ability of the nanocarrier system can be a favourable approach for the management of lung cancer by the inhalation route. Graphical abstract Download : Download high-res image (216KB) Download : Download full-size image

Assessment of nanocarrier mediated afatinib pharmacokinetic: A comparative in-vivo study in rat model for enhanced therapeutic efficacy in lung cancer management